L K Newby

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Markers of cardiac ischemia, injury, and inflammation
    L Kristin Newby
    Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC, USA
    Prog Cardiovasc Dis 46:404-16. 2004
  2. ncbi Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation
    L Kristin Newby
    Duke Clinical Research Institute and the Duke Centers for Education and Research on Therapeutics CERTs, Durham, NC 27715 7969, USA
    J Thromb Thrombolysis 16:119-28. 2003
  3. ncbi Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
    L Kristin Newby
    Centers for Education and Research on Therapeutics, Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circulation 113:203-12. 2006
  4. ncbi Acute coronary syndromes in patients with diabetes mellitus: diagnosis, prognosis, and current management strategies
    Rhoda Brosnan
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715 7969, USA
    Curr Cardiol Rep 5:296-302. 2003
  5. ncbi Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes
    L Kristin Newby
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715 7969, USA
    J Am Coll Cardiol 47:312-8. 2006
  6. ncbi An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A
    L Kristin Newby
    Duke Clinical Research Institute, Durham, NC 27715 7969, USA
    J Thromb Thrombolysis 14:33-42. 2002
  7. ncbi Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations
    L Kristin Newby
    Duke Clinical Research Institute, Durham, NC 27715-7969, USA
    Am Heart J 144:957-80. 2002
  8. ncbi Early statin initiation and outcomes in patients with acute coronary syndromes
    L Kristin Newby
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    JAMA 287:3087-95. 2002
  9. ncbi Acute coronary syndromes in the elderly
    L Kristin Newby
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Cardiovasc Med (Hagerstown) 12:220-2. 2011
  10. ncbi Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 98:1853-9. 1998

Research Grants

  1. MECHANISMS OF HORMONE THERAPY IN POSTMENOPAUSAL WOMEN
    L Newby; Fiscal Year: 2003

Detail Information

Publications101 found, 100 shown here

  1. ncbi Markers of cardiac ischemia, injury, and inflammation
    L Kristin Newby
    Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC, USA
    Prog Cardiovasc Dis 46:404-16. 2004
  2. ncbi Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation
    L Kristin Newby
    Duke Clinical Research Institute and the Duke Centers for Education and Research on Therapeutics CERTs, Durham, NC 27715 7969, USA
    J Thromb Thrombolysis 16:119-28. 2003
    ..While aspirin's secondary prevention benefit is clear, prior reports indicate that 19-83% of eligible patients may not use aspirin chronically...
  3. ncbi Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
    L Kristin Newby
    Centers for Education and Research on Therapeutics, Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Circulation 113:203-12. 2006
    ..Studies have examined the use of evidence-based therapies for coronary artery disease (CAD) in the short term and at hospital discharge, but few have evaluated long-term use...
  4. ncbi Acute coronary syndromes in patients with diabetes mellitus: diagnosis, prognosis, and current management strategies
    Rhoda Brosnan
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715 7969, USA
    Curr Cardiol Rep 5:296-302. 2003
    ..Because diabetes imparts a worse prognosis among patients with acute coronary syndromes, these patients warrant aggressive antiplatelet and antithrombotic therapy, as well as a more invasive management strategy...
  5. ncbi Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes
    L Kristin Newby
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715 7969, USA
    J Am Coll Cardiol 47:312-8. 2006
    ..We sought to evaluate the association between discordant cardiac marker results and in-hospital mortality and treatment patterns in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS)...
  6. ncbi An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A
    L Kristin Newby
    Duke Clinical Research Institute, Durham, NC 27715 7969, USA
    J Thromb Thrombolysis 14:33-42. 2002
    ..We assessed unfractionated heparin infusion regulation by bedside, whole-blood aPTT testing and computerized, algorithmic infusion adjustment, and further evaluated the relationship of achieving the target aPTT with clinical outcomes...
  7. ncbi Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations
    L Kristin Newby
    Duke Clinical Research Institute, Durham, NC 27715-7969, USA
    Am Heart J 144:957-80. 2002
  8. ncbi Early statin initiation and outcomes in patients with acute coronary syndromes
    L Kristin Newby
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    JAMA 287:3087-95. 2002
    ....
  9. ncbi Acute coronary syndromes in the elderly
    L Kristin Newby
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Cardiovasc Med (Hagerstown) 12:220-2. 2011
    ..With consideration of individual preferences for treatment and inherent risks for side-effects in this population, age alone should not determine management of elderly acute coronary syndrome patients...
  10. ncbi Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 98:1853-9. 1998
    ....
  11. ncbi Cost effectiveness of early discharge after uncomplicated acute myocardial infarction
    L K Newby
    Duke Clinical Research Institute, Durham, NC 27715 7969, USA
    N Engl J Med 342:749-55. 2000
    ..Reducing the length of hospitalizations can reduce short-term costs, but there are few data on the long-term clinical and economic consequences of early discharge...
  12. ncbi Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 103:1832-7. 2001
    ..A multimarker strategy (MMS) testing for several markers of myocardial necrosis with different time-to-positivity profiles also may offer clinical advantages...
  13. ncbi Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy
    L K Newby
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 103:2891-6. 2001
    ..Troponin T (TnT) is valuable for short- and long-term risk stratification of patients with acute coronary syndromes (ACS). It also may predict which ACS patients will benefit from glycoprotein (GP) IIb/IIIa blockade...
  14. ncbi Oral platelet glycoprotein IIb/IIIa inhibition
    L K Newby
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27707 7969, USA
    Curr Cardiol Rep 2:372-7. 2000
    ..The oral agents tested in phase III studies thus far have not performed up to expectations, however. The following paper reviews these studies and the implications of their results...
  15. ncbi Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit
    L K Newby
    Duke Clinical Research Institute, Durham, North Carolina 27715 7969, USA
    Am J Cardiol 85:801-5. 2000
    ..0001). Thus, cTnT identified more CPU patients with myocardial necrosis and multivessel CAD than CK-MB and a population with high long-term mortality risk. Routine use of cTnT in CPUs could facilitate risk stratification and management...
  16. ncbi Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Ger
    Karen P Alexander
    Duke University Medical Center, USA
    Circulation 115:2549-69. 2007
    ..Reasons include limited trial data to guide the care of older adults and uncertainty about benefits and risks, particularly with newer medications or invasive treatments and in the setting of advanced age or complex health status...
  17. ncbi Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making
    L K Newby
    The Duke Clinical Research Institute, Durham, NC 27715-7969, USA
    Eur Heart J 24:182-9. 2003
    ..Such time-based risk assessment could guide decision-making in other settings in which randomized studies are impractical...
  18. ncbi Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric
    Karen P Alexander
    Duke University Medical Center, USA
    Circulation 115:2570-89. 2007
    ....
  19. ncbi Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:611-4. 2005
    ..7% vs 48.0% with >/=50% ST-segment resolution, p = 0.03) and sustained over 180 minutes after drug administration; this transient benefit may suggest a time frame when more optimal percutaneous coronary intervention can be performed...
  20. ncbi Cardiac markers: point of care testing
    M P Hudson
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Clin Chim Acta 284:223-37. 1999
    ....
  21. ncbi Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome
    Hassan Kassem-Moussa
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 148:439-46. 2004
    ..CONCLUSIONS: In patients stabilized after presenting with a spectrum of ACS and treated with sibrafiban and/or aspirin, stroke occurred in fewer than 1% within 90 days but carried a significant mortality and morbidity risk...
  22. ncbi Postmenopausal hormone use in women with acute coronary syndromes
    Elizabeth Parsons
    Duke University School of Medicine, Durham, North Carolina, USA
    J Womens Health (Larchmt) 13:863-71. 2004
    ..These results are consistent with the absence of benefit from HRT use (combination or estrogen only) in previous studies in more stable populations...
  23. ncbi Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes
    Kyla M Bennett
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
    Am J Cardiol 99:1351-6. 2007
    ..Guideline-recommended therapies and interventions are under-utilized in patients with NSTE ACS and HF, with and without preserved systolic function, compared with those without HF...
  24. ncbi Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Usin
    J H Alexander
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 283:347-53. 2000
    ..Controversy surrounds the diagnostic and prognostic importance of slightly elevated cardiac markers in patients with acute coronary syndromes without ST-segment elevation...
  25. ncbi Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients
    Padma Kaul
    Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
    J Am Coll Cardiol 41:371-80. 2003
    ..4 vs. 1.5). CONCLUSIONS: Quantitative ST and cTnT status are complementary in assessing risk among ACS patients and both should be employed to determine prognosis and assist in medical decision making...
  26. ncbi Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 51:991-6. 2008
    ..Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non-ST-segment elevation acute coronary syndromes (NSTE ACS) patients...
  27. ncbi Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)
    Thaddeus R Tolleson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 92:330-3. 2003
    ..These patients and their outcomes may be more representative of patients with typical acute coronary syndromes undergoing stenting in clinical practice...
  28. ncbi Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes
    Ankie Amos
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715-7969, USA
    Curr Cardiol Rep 7:263-9. 2005
    ..Importantly, biomarkers of different processes may be combined to enhance risk stratification above that of any single marker...
  29. ncbi C-reactive protein: a novel marker of cardiovascular risk
    Svati H Shah
    Department of Cardiology, Duke University Medical Center, Durham, North Carolina, USA
    Cardiol Rev 11:169-79. 2003
    ..This review presents an overview of the data regarding CRP measurement for cardiovascular risk assessment...
  30. ncbi Predictors of 90-day outcome in patients stabilized after acute coronary syndromes
    L K Newby
    Duke Clinical Research Institute, Durham, NC 27715-7969, USA
    Eur Heart J 24:172-81. 2003
    ..Typical clinical markers are better at identifying risk of death than non-fatal MI or SRI. Novel risk markers are needed for these outcomes...
  31. ncbi Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation
    R D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707, USA
    Heart 94:867-73. 2008
    ....
  32. ncbi Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
    K P Alexander
    Outcomes Research and Assessment Group, The Duke Clinical Research Institute, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 38:1-7. 2001
    ..This study explored the association between the initiation of hormone replacement therapy (HRT) and early cardiac events (<1 year) in women with a recent myocardial infarction (MI)...
  33. ncbi Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials
    John M Galla
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 151:16-24. 2006
    ..All patients with ACS should have CK-MB measurement to search for cardiac ischemia. Patients with elevated CK-MB should receive aggressive management commensurate with their increased risks...
  34. ncbi Use of guidelines-recommended management and outcomes among women and men with low-level troponin elevation: insights from CRUSADE
    Sharif A Halim
    Department of Medicine and the Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715 7969, USA
    Circ Cardiovasc Qual Outcomes 2:199-206. 2009
    ..5x ULN) remains uncertain. Using the CRUSADE database, we explored relationships between sex and treatment and outcomes among patients with troponin 1 to 1.5x ULN...
  35. ncbi Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical
    Camille G Frazier
    Duke University Medical Center, Clinical Research Institute, Durham, NC, USA
    Am Heart J 150:1260-7. 2005
    ..Opportunities exist to improve medical therapy and outcomes in women with hypertension...
  36. ncbi Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes
    Jason N Katz
    Department of Medicine, Division of Cardiology and Pulmonary and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Crit Care Med 38:375-81. 2010
    ..To describe long-term temporal trends in patient characteristics, processes of care, and in-hospital outcomes among unselected admissions within the contemporary coronary care unit...
  37. ncbi Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes
    L Kristin Newby
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Am Coll Cardiol 41:31S-36S. 2003
    ..This paper will review the evolution of these important roles of troponin testing for risk stratification in ACS...
  38. ncbi Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)
    Melvin R Echols
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 99:315-21. 2007
    ..African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients...
  39. ncbi Comparison of 30-day outcome, resource use, and coronary artery disease severity in patients with suspected coronary artery disease with and without diabetes mellitus assigned to chest pain units
    Carlos D Sánchez
    Duke University School of Medicine and Duke Clinical Research Institute, Durham, North Carolina 27715 7969, USA
    Am J Cardiol 91:1228-30. 2003
  40. ncbi Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease
    Svati H Shah
    Duke University Medical Center, Durham, NC, USA
    Am Heart J 160:371-379.e2. 2010
    ..Clinical predictive models leave gaps in our ability to stratify cardiovascular risk. High-throughput molecular profiling promises to improve risk classification...
  41. ncbi The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events
    L Kristin Newby
    Duke Clinical Research Institute, Durham, North Carolina 27707, USA
    Am J Med 112:647-58. 2002
    ..03 to 1.29). CONCLUSION: Oral glycoprotein IIb/IIIa inhibitor therapy is associated with increased mortality and myocardial infarction. No single explanation for these findings is satisfactory; the problem is likely to be multifactorial...
  42. ncbi A comparison of acute coronary syndrome care at academic and nonacademic hospitals
    Manesh R Patel
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am J Med 120:40-6. 2007
    ..We sought to identify hospital characteristics associated with high levels of adherence in order to gain insight into successful processes of care...
  43. ncbi Platelet inhibitors: what are the data in women?
    Michael W Tempelhof
    Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27715 7969, USA
    Cardiol Rev 16:23-9. 2008
    ....
  44. ncbi Apixaban with antiplatelet therapy after acute coronary syndrome
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:699-708. 2011
    ..Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome...
  45. ncbi Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS)
    C D Bushnell
    Department of Medicine, Duke Center for Cerebrovascular Disease, Division of Cardiology Durham, NC, USA
    Neurology 62:968-70. 2004
    ..52, 95% CI 0.23 to 1.18, p = 0.12), fatal ischemic stroke (RH 0.51, 95% CI 0.18 to 1.45, p = 0.21), fatal hemorrhagic stroke (RH 0.18, 95% CI 0.02 to 1.46, p = 0.11), or TIA (RH 1.32, 95% CI 0.84 to 2.09, p = 0.23)...
  46. ncbi Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early
    Manesh R Patel
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 152:641-7. 2006
    ..We sought to determine the prevalence, predictors, and outcomes of patients with NSTEMI and insignificant CAD...
  47. ncbi Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian white Americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative
    Tracy Y Wang
    Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 100:391-6. 2007
    ..Further investigation is needed to explore the potential for ethnic variability in antithrombotic susceptibility...
  48. ncbi Present and evolving role of eptifibatide in the treatment of acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 5:401-12. 2007
    ....
  49. ncbi Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative
    Karen P Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    Circulation 114:1380-7. 2006
    ..The contribution of dosing to the observed sex-related differences in bleeding is unknown...
  50. ncbi Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women
    Andrew Sherwood
    Duke University Medical Center, Durham, NC 27710, USA
    Arterioscler Thromb Vasc Biol 27:1782-7. 2007
    ..We evaluated age and coronary heart disease (CHD) as potential moderators of the effects of 17beta-estradiol on vascular endothelial function in postmenopausal women...
  51. ncbi Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
    Pierluigi Tricoci
    Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
    Circulation 116:2669-77. 2007
    ..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
  52. ncbi Representation of women in randomized clinical trials of cardiovascular disease prevention
    Chiara Melloni
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 3:135-42. 2010
    ....
  53. ncbi Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes
    Renato D Lopes
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am J Med 123:134-40. 2010
    ....
  54. ncbi Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 104:175-81. 2009
    ..Patient education, better prescription drug coverage, and reminder strategies may improve use of EBMs at 3 months after discharge from ACS admission...
  55. ncbi Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
    Richard C Becker
    Duke Clinical Research Institute, Durham, NC, USA
    Lancet 373:919-28. 2009
    ..We therefore assessed the tolerability and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist...
  56. ncbi Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cardiol 31:125-9. 2008
    ..The prognostic value of cardiac troponins (cTn) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and chronic kidney disease (CKD) is debated...
  57. ncbi ALOX5AP variants are associated with in-stent restenosis after percutaneous coronary intervention
    Svati H Shah
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States
    Atherosclerosis 201:148-54. 2008
    ..There is no accurate way to predict in-stent restenosis, although risk factors for atherosclerosis overlap those for in-stent restenosis. Therefore, we evaluated atherosclerosis candidate genes for association with in-stent restenosis...
  58. ncbi Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome
    Tracy Y Wang
    Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Cardiol 32:E22-8. 2009
    ..Hypercholesterolemia is a risk factor for coronary artery disease, yet is associated with lower risk of adverse outcomes in patients with acute coronary syndromes (ACS)...
  59. ncbi GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
    Pierluigi Tricoci
    Division of Cardiovascular Medicine, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    Cardiol Rev 16:89-94. 2008
    ..The availability of new antiplatelet and antithrombotic drugs renders even more complex the question of the best strategy...
  60. ncbi International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 101:25-29. 2008
    ....
  61. ncbi Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study
    Chiara Melloni
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 6:9-16. 2008
    ....
  62. ncbi Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events
    Svati H Shah
    Department of Medicine, Duke University, Durham, NC, USA
    Circ Cardiovasc Genet 3:207-14. 2010
    ..Molecular tools may provide insight into cardiovascular risk. We assessed whether metabolites discriminate coronary artery disease (CAD) and predict risk of cardiovascular events...
  63. ncbi Statin use and sex-specific stroke outcomes in patients with vascular disease
    Cheryl D Bushnell
    Center for Cerebrovascular Disease, Duke University Medical Center, Durham, NC 27710, USA
    Stroke 37:1427-31. 2006
    ..We investigated the relationships between statin use and sex-specific stroke incidence, severity, and mortality...
  64. ncbi Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 292:1555-62. 2004
    ..It is unclear if blood transfusion in anemic patients with acute coronary syndromes is associated with improved survival...
  65. ncbi Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Ann Emerg Med 45:355-62. 2005
    ....
  66. ncbi Poverty, process of care, and outcome in acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, dDuke University, PO Box 17969, Durham, NC 27715, USA
    J Am Coll Cardiol 41:1948-54. 2003
    ..We sought to determine whether income-based disparities in care processes and outcome exist in patients with acute coronary syndromes...
  67. ncbi Seeking the optimal aspirin dose in acute coronary syndromes
    David F Kong
    Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 90:622-5. 2002
  68. ncbi The significance of elevated troponin T in patients with nondialysis-dependent renal insufficiency: a validation with coronary angiography
    John F Heitner
    Department of Medicine, Division of Cardiology, New York Methodist Hospital, 506 6th Street, 2 Buckley Pavilion, Brooklyn, NY 11215, USA
    Clin Cardiol 28:333-6. 2005
    ....
  69. ncbi Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes
    Matthew T Roe
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Arch Intern Med 165:1870-6. 2005
    ..The threshold of troponin elevation that stimulates changes in clinical decision making for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACSs) has not been previously evaluated...
  70. ncbi Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes
    Eric L Eisenstein
    Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC 27715, USA
    Am J Med 118:981-90. 2005
    ..We evaluated the relationship between elevated body mass index (BMI) and 30-day, 90-day, and 1-year clinical outcomes postacute coronary syndromes...
  71. ncbi Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
    Sunil V Rao
    The Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 96:1200-6. 2005
    ..Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS...
  72. ncbi Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes
    Karen P Alexander
    Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
    JAMA 294:3108-16. 2005
    ..Effective medical care assumes delivery of evidence-based medicines to appropriate patients with doses comparable to those studied...
  73. ncbi Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge
    Pierluigi Tricoci
    Division of Cardiology, Duke University School of Medicine, and Duke Clinical Research Institute, Durham, NC, USA
    Arch Intern Med 166:806-11. 2006
    ....
  74. ncbi Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes
    Sunil V Rao
    Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
    Am J Cardiol 91:936-40. 2003
    ..This suggests that these patients should be admitted to the hospital and monitored in either an intensive care or step-down unit...
  75. ncbi Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Netwo
    Kenneth W Mahaffey
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 143:242-8. 2002
    ..We examined disagreement between investigator and clinical events committee (CEC) reporting of MIs in an international, randomized trial...
  76. ncbi A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes
    Sunil V Rao
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 47:809-16. 2006
    ..The goal of this study was to determine the association between Thrombolysis In Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding and clinical outcomes...
  77. ncbi Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 156:209-15. 2008
    ..Unfractionated heparin (UFH) is a mainstay of treatment for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), but the practice of weight-adjusted bolus and infusion dosing has not been carefully evaluated...
  78. ncbi International differences in evolution of early discharge after acute myocardial infarction
    Padma Kaul
    University of Alberta, Edmonton, Alberta, Canada
    Lancet 363:511-7. 2004
    ..We aimed to identify the extent to which countries have taken advantage of the opportunity for early discharge...
  79. ncbi Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes
    Darren K McGuire
    Donald W Reynolds Cardiovascular Clinical Research Center at the University of Texas Southwestern Medical Center, Dallas, Tex, USA
    Am Heart J 147:246-52. 2004
    ..The relative effect of glucose-lowering strategies of "insulin provision" versus "insulin sensitization" among patients with CAD remains unclear...
  80. ncbi Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes
    Michael H Yen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Med 115:318-21. 2003
  81. ncbi Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience
    W Brian Gibler
    Department of Emergency Medicine, University of Cincinnati, Cincinnati OH, USA
    Ann Emerg Med 39:123-30. 2002
    ....
  82. ncbi Prognostic significance of elevated troponin I after percutaneous coronary intervention
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, 30 Bond Street, Toronto, Ontario, Canada M5B 1W8
    J Am Coll Cardiol 39:1738-44. 2002
    ..We sought to assess the incidence and clinical significance of elevated cardiac troponin I (cTnI) after percutaneous coronary intervention (PCI)...
  83. ncbi Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women
    Warren J Cantor
    St Michael s Hospital, Toronto, Ontario, Canada
    Am Heart J 144:297-302. 2002
    ..Differences in target vessel size may partially account for these differences. We set out to explore the effects of sex, body surface area (BSA), and target coronary vessel size on clinical outcomes after angioplasty...
  84. ncbi Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction
    Ronnier J Aviles
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44951, USA
    N Engl J Med 346:2047-52. 2002
    ..However, there is concern that renal dysfunction may impair the prognostic value, because cardiac troponin T may be cleared by the kidney...
  85. ncbi Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
    Deborah Grady
    Department of Epidemiology and Biostatistics, University of California, San Francisco, 74 New Montgomery St, Suite 600, San Francisco, CA 94105, USA
    JAMA 288:49-57. 2002
    ..However, in the hormone group, findings did suggest a higher risk of CHD events during the first year, and a decreased risk during years 3 to 5...
  86. ncbi Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology
    James McCord
    Henry Ford Hospital
    Circulation 117:1897-907. 2008
  87. ncbi The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis
    Ellis W Lader
    Circulation 109:e305-7. 2004
  88. ncbi Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies
    James L Januzzi
    Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Am Heart J 151:360-6. 2006
    ..Troponin testing is useful for evaluating patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS); however, a significant percentage of patients are troponin negative at presentation and develop late rise of the marker...
  89. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Clin Chem 53:552-74. 2007
  90. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes
    David A Morrow
    Brigham and Women's Hospital, Harvard University, Boston, MA, USA
    Circulation 115:e356-75. 2007
  91. ncbi National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes
    Fred S Apple
    Hennepin County Medical Center, Minneapolis, MN, USA
    Circulation 115:e352-5. 2007
  92. ncbi Does ranolazine have a place in the treatment of acute coronary syndromes?
    L Kristin Newby
    JAMA 297:1823-5. 2007
  93. ncbi ACCF/AHA/SCAI 2007 update of the Clinical Competence Statement on Cardiac Interventional Procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and
    Spencer B King
    Circulation 116:98-124. 2007
  94. ncbi Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department
    W Brian Gibler
    University of Cincinnati College of Medicine, USA
    Ann Emerg Med 46:185-97. 2005
    ..Despite publication of the guidelines several years ago, many patients with UA/NSTEMI still do not receive guidelines-indicated therapy...
  95. ncbi Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials
    Cheuk Kit Wong
    Cardiology, Dunedin School of Medicine, Otago University, Dunedin, New Zealand
    Am Heart J 154:313-21. 2007
    ..Evidence-based medications (EBM) are underused in older patients despite potentially larger absolute benefits. Little is known about factors influencing prescribing in the elderly with acute coronary syndromes...
  96. ncbi Renal function, concomitant medication use and outcomes following acute coronary syndromes
    Donal N Reddan
    University College Galway, Ireland
    Nephrol Dial Transplant 20:2105-12. 2005
    ..We also explored the associations of CKD with prescription patterns for common cardiovascular medications and the association of these prescription patterns with clinical outcomes...
  97. ncbi The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with n
    Robert P Giugliano
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:994-1002. 2005
    ..However, the guidelines are not explicit regarding the timing of initiation of GpIIb-IIIa antagonists, and there is marked variation in clinical practice regarding their use...
  98. ncbi Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementatio
    Andra L Blomkalns
    Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0769, USA
    J Am Coll Cardiol 45:832-7. 2005
    ..We hypothesized that significant disparities in gender exist in the management of patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS)...
  99. ncbi Lessons learned from a clinical trial
    Paul W Armstrong
    University of Alberta, Edmonton, Alberta, Canada
    Circulation 110:3610-4. 2004
  100. ncbi Association of race with complications and prognosis following acute coronary syndromes
    Craig R Asher
    Department of Cardiology, The Cleveland Clinic Foundation, Weston, Florida, USA
    Am J Cardiol 94:792-4. 2004
    ..The 1-year mortality rate was 2.9% for black patients and 2.5% for non-black patients (p = 0.93)...
  101. ncbi National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure
    W H Wilson Tang
    Circulation 116:e99-109. 2007

Research Grants1

  1. MECHANISMS OF HORMONE THERAPY IN POSTMENOPAUSAL WOMEN
    L Newby; Fiscal Year: 2003
    ....